Lipid-lowering and antiatherogenic effects of Vitex megapotamica (Spreng.) Moldenke in a mice experimental model

Publication date: 6 April 2018
Source:Journal of Ethnopharmacology, Volume 215
Author(s): Vanessa Aranega Pires, Euclides Lara Cardozo-Junior, Caroline Flach Ortmann, Jhonatan Christian Maraschin, Wagner Alex Jann Favreto, Carmen Maria Donaduzzi, Flávio Henrique Reginatto, Jamil Assreuy
Ethnopharmacological relevanceVitex megapotamica (Spreng.) Moldenke is a deciduous tree, native of South America. Its leaves are traditionally used to treat cardiovascular diseases. This activity is related to the presence of flavonoids, the major compounds of the crude extract.Aim of the studyThis study investigated the effects of the oral administration of crude extract and standardized fractions from V. megapotamica leaves on lipid profile and on the formation of atherosclerotic plaque in C57BL/6 LDLr-KO mice treated with high-fat diet (HFD).Materials and methodsMale C57BL/6 LDLr-KO mice were fed with HFD (cholesterol, 1.25%) for 30 days. They were treated with hydroethanolic extract (500 or 1000mg/kg/day) or fractions (125 or 250mg/kg/day). After 30 days of treatment, it was evaluated the serum lipid profile, atherogenic index, and atherosclerotic plaque.ResultsAll doses of the hydroethanolic extract reduced significantly the levels of total cholesterol, triglycerides, LDL-c and the atherogenic index. The n-butanolic fraction also reduced significantly the levels of total cholesterol, triglycerides, LDL-c and the atherogenic index, at all doses, with exception for the triglycerides, which only the lower dose was effective. The residual fraction reduced significantly the levels of total cholesterol, LDL-c and the atherogenic index, at all doses, with exception for the atherogenic index, which only the higher dose was effective. The atherosclerotic plaque formation was impaired only by the lower dose of the hydroethanolic extract.ConclusionsOverall, our data suggest that V. megapotamica has potential for the treatment of dyslipidemias.

Graphical abstract

http://ift.tt/2lvjLA9